In vitro activities of ceftobiprole, dalbavancin, daptomycin, linezolid, and tigecycline against methicillin-resistant Staphylococcus aureus blood isolates: Stratified analysis by vancomycin MIC

Diagnostic Microbiology and Infectious Disease

Volumn 73, Issue 3, 2012, Pages 264-266

  Chong, Yong Pil ^a,b   Park, Su Jin ^a,b   Kim, Hee Sueng ^a,b   Kim, Eun Sil ^a,b   Kim, Mi Na ^a   Kim, Sung Han ^a,b   Lee, Sang Oh ^a,b   Choi, Sang Ho ^a,b   Jeong, Jin Yong ^a,b   Woo, Jun Hee ^a,b   Kim, Yang Soo ^a,b  

^a University of Ulsan College of Medicine   (South Korea)

^b University of Ulsan   (South Korea)

Author keywords

Antibiotics; Bacteremia; MRSA; Susceptibility

Indexed keywords

CEFTOBIPROLE; DALBAVANCIN; DAPTOMYCIN; LINEZOLID; METICILLIN; PENICILLIN BINDING PROTEIN 2A; TIGECYCLINE; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIUM ISOLATE; BLOOD CULTURE; BROTH DILUTION; CONCENTRATION RESPONSE; HUMAN; IN VITRO STUDY; MECA GENE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; BACTEREMIA; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; STAPHYLOCOCCAL INFECTIONS;

EID: 84862212660     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2012.01.015     Document Type: Article

References (19)

1. Ambrose P.G., Meagher A.K., Passarell J.A., Van Wart S.A., Cirincione B.B., Bhavnani S.M., et al. Application of patient population-derived pharmacokinetic-pharmacodynamic relationships to tigecycline breakpoint determination for staphylococci and streptococci. Diagn. Microbiol. Infect. Dis. 2009, 63:155-159.
2. Barbour A., Schmidt S., Ma B., Schiefelbein L., Rand K.H., Burkhardt O., et al. Clinical pharmacokinetics and pharmacodynamics of tigecycline. Clin. Pharmacokinet. 2009, 48:575-584.
3. Biedenbach D.J., Ross J.E., Fritsche T.R., Sader H.S., Jones R.N. Activity of dalbavancin tested against Staphylococcus spp. and beta-hemolytic Streptococcus spp. isolated from 52 geographically diverse medical centers in the United States. J.Clin. Microbiol. 2007, 45:998-1004.
4. Clinical and Laboratory Standards Institute (CLSI) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, M7-A8 2009, CLSI, Wayne, PA.
5. Cosgrove S.E., Fowler V.G. Management of methicillin-resistant Staphylococcus aureus bacteremia. Clin. Infect. Dis. 2008, 46(Suppl 5):S386-S393.
6. Cui L., Tominaga E., Neoh H.M., Hiramatsu K. Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 2006, 50:1079-1082.
7. Gardiner D., Dukart G., Cooper A., Babinchak T. Safety and efficacy of intravenous tigecycline in subjects with secondary bacteremia: pooled results from 8 phase III clinical trials. Clin. Infect. Dis. 2010, 50:229-238.
8. Gould I.M., Cauda R., Esposito S., Gudiol F., Mazzei T., Garau J. Management of serious meticillin-resistant Staphylococcus aureus infections: what are the limits?. Int. J. Antimicrob. Agents 2011, 37:202-209.
9. Huang Y.T., Liao C.H., Teng L.J., Hsueh P.R. Comparative bactericidal activities of daptomycin, glycopeptides, linezolid and tigecycline against blood isolates of Gram-positive bacteria in Taiwan. Clin. Microbiol. Infect. 2008, 14:124-129.
10. Keel R.A., Sutherland C.A., Aslanzadeh J., Nicolau D.P., Kuti J.L. Correlation between vancomycin and daptomycin MIC values for methicillin-susceptible and methicillin-resistant Staphylococcus aureus by 3 testing methodologies. Diagn. Microbiol. Infect. Dis. 2010, 68:326-329.
11. Lodise T.P., Graves J., Evans A., Graffunder E., Helmecke M., Lomaestro B.M., et al. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob. Agents Chemother. 2008, 52:3315-3320.
12. Meagher A.K., Ambrose P.G., Grasela T.H., Ellis-Grosse E.J. The pharmacokinetic and pharmacodynamic profile of tigecycline. Clin. Infect. Dis. 2005, 41(Suppl 5):S333-S340.
13. Moore C.L., Osaki-Kiyan P., Haque N.Z., Perri M.B., Donabedian S., Zervos M.J. Daptomycin versus vancomycin for bloodstream infections due to methicillin-resistant Staphylococcus aureus with a high vancomycin minimum inhibitory concentration: a case-control study. Clin. Infect. Dis. 2012, 54:51-58.
14. Mouton J.W., Schmitt-Hoffmann A., Shapiro S., Nashed N., Punt N.C. Use of Monte Carlo simulations to select therapeutic doses and provisional breakpoints of BAL9141. Antimicrob. Agents Chemother. 2004, 48:1713-1718.
15. Patel N., Lubanski P., Ferro S., Bonafede M., Harrington S., Evans A., et al. Correlation between vancomycin MIC values and those of other agents against Gram-positive bacteria among patients with bloodstream infections caused by methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 2009, 53:5141-5144.
16. Song J.H., Hsueh P.R., Chung D.R., Ko K.S., Kang C.I., Peck K.R., et al. Spread of methicillin-resistant Staphylococcus aureus between the community and the hospitals in Asian countries: an ANSORP study. J. Antimicrob. Chemother. 2011, 66:1061-1069.
17. Soriano A., Marco F., Martinez J.A., Pisos E., Almela M., Dimova V.P., et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin. Infect. Dis. 2008, 46:193-200.
18. Steinkraus G., White R., Friedrich L. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05. J. Antimicrob. Chemother. 2007, 60:788-794.
19. Watanabe Y., Neoh H.M., Cui L., Hiramatsu K. Improved antimicrobial activity of linezolid against vancomycin-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 2008, 52:4207-4208.